Celecoxib

Generic Name: Celecoxib

Brand Names: Celebrex, Elyxyb, Seglentis

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₄F_₃N_₃O_₂S

CAS Number: 169590-42-5

Unique Ingredient Identifier: JCX84Q7J1L

Background: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication: Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions: Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain

Associated Therapies: -

Clinical Trials

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: Naproxen Sodium (Aleve, BAY117031)
Drug: Acetaminophen ER
Drug: Celecoxib
Drug: Placebo

First Posted Date: 2018-06-27

Last Posted Date: 2020-06-19

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT03570554

Locations: 🇺🇸
Radiant Research, Inc., San Antonio, Texas, United States

Different Kinds of Acupuncture Treatment for Knee Osteoarthritis

Not Applicable

Completed

Conditions: Knee Osteoarthritis

Interventions: Other: treatment2
Other: treatment4
Other: treatment1
Other: treatment3
Other: treatment5
Drug: Celebrex

First Posted Date: 2018-06-20

Last Posted Date: 2023-06-08

Lead Sponsor: Zhejiang Chinese Medical University

Target Recruit Count: 360

Registration Number: NCT03563690

Locations: 🇨🇳
The third affiliated hospital of Zhejiang CMU, Hangzhou, Zhejiang, China

Opioid-Free Shoulder Arthroplasty

Phase 4

Completed

Conditions: Arthritis;Inflammatory
Opioid Use
Shoulder Osteoarthritis
Avascular Necrosis
Rotator Cuff Tear

Interventions: Drug: Gabapentin
Drug: Celecoxib
Drug: toradol
Drug: acetaminophen
Drug: regional block
Drug: propofol
Drug: IV lidocaine
Drug: rocuronium
Drug: vecuronium
Drug: sevoflurane
Drug: desflurane

First Posted Date: 2018-05-30

Last Posted Date: 2020-10-14

Lead Sponsor: OrthoCarolina Research Institute, Inc.

Target Recruit Count: 86

Registration Number: NCT03540030

Locations: 🇺🇸
OrthoCarolina Research Institute, Charlotte, North Carolina, United States

Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis

Phase 4

Terminated

Conditions: Ankylosing Spondylitis
Axial Spondyloarthritis

Interventions: Drug: Meloxicam
Drug: Indomethacin
Drug: Diclofenac
Drug: Celecoxib

First Posted Date: 2018-03-22

Last Posted Date: 2020-09-22

Lead Sponsor: Columbia University

Target Recruit Count: 9

Registration Number: NCT03473665

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

MAST Trial: Multi-modal Analgesic Strategies in Trauma

Phase 4

Completed

Conditions: Nonspecific Pain Post Traumatic Injury

Interventions: Drug: Acetaminophen IV/PO
Drug: Acetaminophen PO
Drug: Ketorolac
Drug: Celebrex
Drug: Naproxen
Drug: Tramadol
Drug: Regional anesthesia
Drug: Pregabalin
Drug: Gabapentin
Drug: Lidocaine
Drug: Opioids

First Posted Date: 2018-03-21

Last Posted Date: 2021-06-18

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 1561

Registration Number: NCT03472469

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA

Phase 4

Conditions: Knee Osteoarthritis

Interventions: Drug: Diacerein
Drug: Celecoxib

First Posted Date: 2018-01-19

Last Posted Date: 2018-02-26

Lead Sponsor: Whan-Seok Choi

Target Recruit Count: 90

Registration Number: NCT03404479

Locations: 🇰🇷
Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Metastatic Carcinoma in the Liver
Recurrent Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7